BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 24664)

  • 21. Bone marrow transplantation with T-cell-depleted grafts. II. Reconstitution of immunohemopoietic functions in lethally irradiated mice transplanted with unseparated or T-cell-depleted bone marrow grafts disparate at minor histocompatibility antigens.
    Leshem B; Tsuberi BZ; Lebendiker Z; Anafi-Ayalon M; Shalit M; Weiss L; Slavin S; Kedar E
    Transplantation; 1987 Jun; 43(6):814-7. PubMed ID: 2954282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transfer of immunity by transfer of bone marrow cells: a requirement for T lymphocytes and sensitivity to cyclophosphamide.
    Marusić M
    Exp Hematol; 1978 Oct; 6(9):725-37. PubMed ID: 361429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mitigation of Graft-versus-host disease in mice with xenogeneic antithymocyte serum and complement.
    Volf D; Sensenbrenner LL; Santos GW
    Exp Hematol; 1976 Nov; 4(6):354-64. PubMed ID: 11110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Restitution of the thymus in lethally irradiated mice after transplantation of syngeneic or allogeneic bone marrow.
    Müller-Hermelink HK; Gülden M; Bathmann R
    Immunobiology; 1984 Dec; 167(5):462-82. PubMed ID: 6396224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of lethal graft-versus-host disease in mice by monoclonal antibodies directed against T cells or their subsets. I. Evidence for the induction of a state of tolerance based on suppression.
    Knulst AC; Tibbe GJ; Noort WA; Bril-Bazuin C; Benner R; Savelkoul HF
    Bone Marrow Transplant; 1994 Mar; 13(3):293-301. PubMed ID: 8199571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adaptive phenomena in bone marrow transplantation.
    Goujet-Zalc C; Ilbery PL
    Exp Hematol; 1973; 1(1):3-10. PubMed ID: 4154047
    [No Abstract]   [Full Text] [Related]  

  • 27. Graft-vs-host reactions (GVHR) across minor murine histocompatibility barriers. II. Development of natural suppressor cell activity.
    Maier T; Holda JH; Claman HN
    J Immunol; 1985 Sep; 135(3):1644-51. PubMed ID: 3160774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.
    Blazar BR; Taylor PA; Snover DC; Bluestone JA; Vallera DA
    J Immunol; 1993 Jan; 150(1):265-77. PubMed ID: 8417127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic reconstitution after nonmyeloablative conditioning: mitigation of graft-versus-host and host-versus-graft reactivity by anti-CD44v6.
    Christ O; Günthert U; Schmidt DS; Zöller M
    J Leukoc Biol; 2002 Jan; 71(1):33-46. PubMed ID: 11781378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abrogation of hybrid resistance to bone marrow engraftment by graft-vs-host-induced immune deficiency.
    Hakim FT; Shearer GM
    J Immunol; 1986 Nov; 137(10):3109-16. PubMed ID: 3095424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antilymphocytic antibodies and marrow transplantation. V. Suppression of secondary disease by host-versus-theta-graft reaction.
    Thierfelder S; Rodt H
    Transplantation; 1977 Jan; 23(1):87-92. PubMed ID: 319574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lethal irradiation: treatment with immune cell populations.
    Mandel MA
    Ann Plast Surg; 1979 Mar; 2(3):213-8. PubMed ID: 44168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation.
    Truitt RL; Johnson BD; Hanke C; Talib S; Hearst JE
    J Immunol; 1999 Nov; 163(9):5145-56. PubMed ID: 10528221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A study of proliferative responses to host Ia antigens in fully allogeneic bone marrow chimeras in mice--sequential analysis of the reactivity and characterization of the cells involved in the response].
    Iwabuchi K
    Hokkaido Igaku Zasshi; 1986 Nov; 61(6):869-82. PubMed ID: 3493963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetically determined resistance to foreign bone marrow transplantation in mice: characterization of the effector cells.
    Miller SC
    J Immunol; 1983 Jul; 131(1):92-7. PubMed ID: 6345669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A correlation between conditioning and engraftment in recipients of MHC-mismatched T cell-depleted murine bone marrow transplants.
    Soderling CC; Song CW; Blazar BR; Vallera DA
    J Immunol; 1985 Aug; 135(2):941-6. PubMed ID: 3891856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic resistance in the graft-versus-host reaction.
    Sula K; Nouza K
    Exp Clin Immunogenet; 1984; 1(3):175-84. PubMed ID: 6101099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term immunologic tolerance induction in chimeric mice after bone marrow transplantation across major histocompatibility barriers: persistent or redeveloping immunologic responsiveness after prolonged survival.
    Sugiura K; Yasumizu R; Iwai H; Inaba MM; Toki J; Ogura M; Hara I; Good RA; Ikehara S
    Thymus; 1991 Nov; 18(3):137-53. PubMed ID: 1838450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progress in the prevention of GVH: bone marrow grafts after ALG conditioning, with lymphocyte split chimerism, use of a lymphocyte "chalone T", and soluble histocompatibility antigens.
    Mathé G; Kiger N; Florentin I; Garcia-Giralt E; Martyre MC; Halle-Pannenko O; Schwartzenberg L
    Transplant Proc; 1973 Mar; 5(1):933-9. PubMed ID: 4144474
    [No Abstract]   [Full Text] [Related]  

  • 40. Leucyl-leucine methyl ester treatment of donor cells permits establishment of immunocompetent parent----F1 chimeras that are selectively tolerant of host alloantigens.
    Thiele DL; Calomeni JA; Lipsky PE
    J Immunol; 1987 Oct; 139(7):2137-42. PubMed ID: 3309052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.